- Vertex Stock Tumbles 15% After Strong Earnings. What’s Spooking Investors. Barron’s
- Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings The Wall Street Journal
- Vertex’s trial failure, scrapped study cloud pain drug push; shares slump Reuters
- Vertex’s top scientist Altshuler to retire, next-generation pain drug fails Endpoints News
- Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain Yahoo Finance
Source link
